

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 November 2004 (25.11.2004) ✓

PCT

(10) International Publication Number
WO 2004/101518 A1 ✓

(51) International Patent Classification⁷: **C07D 211/54**,
417/06, 401/12, 413/12, A61K 31/445, A61P 25/00

(74) Agent: BUCHAN, Gavin, MacNicol; Terlings Park, East-
wick Road, Harlow, Essex CM20 2QR (GB).

(21) International Application Number:
PCT/GB2004/001998 ✓

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(22) International Filing Date: 7 May 2004 (07.05.2004) ✓

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0311349.5 16 May 2003 (16.05.2003) GB

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): **MERCK
SHARP & DOHME LIMITED** [GB/GB]; Hertford Road,
Hoddesdon, Hertfordshire EN11 9BU (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **GILLIGAN, Myra**
[IE/GB]; Terlings Park, Eastwick Road, Harlow, Essex
CM20 2QR (GB). **HUMPHRIES, Alexander, Charles**
[GB/GB]; Terlings Park, Eastwick Road, Harlow, Es-
sex CM20 2QR (GB). **LADDUWAHETTY, Tamara**
[GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex
CM20 2QR (GB).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: 4-ARYLSULPHONYLPYPERIDINE DERIVATIVES FOR ANTAGONISM OF THE 5-HT_{2A} RECEPTOR



(57) Abstract: Compounds of formula (I): are selective antagonists of the 5-HT_{2A} receptor, and hence are useful in treatment of adverse conditions at the central nervous system, such as sleep disorders and schizophrenia.

WO 2004/101518 A1

THIS PAGE BLANK (USPTO)

JC20 Rec'd PCT/PTO 11 OCT 2005

**4-ARYLSULPHONYLPIPERIDINE DERIVATIVES FOR ANTAGONISM OF
THE 5-HT_{2A} RECEPTOR**

The present invention relates to a class of sulphonyl derivatives which act on
5 serotonin receptors (also known as 5-hydroxytryptamine or 5-HT receptors). More
particularly, the invention concerns 4-arylsulphonylpiperidine derivatives which bear a
fluorine substituent in the 4-position. These compounds are potent and selective
antagonists of the human 5-HT_{2A} receptor and are therefore useful as pharmaceutical
agents, especially in the treatment and/or prevention of adverse conditions of the
10 central nervous system, including sleep disorders such as insomnia, psychotic
disorders such as schizophrenia and psychiatric disorders such as anxiety.

Compounds of the invention typically display more effective binding to the
human 5-HT_{2A} receptor than to other human receptors such as D₂, 5HT_{2C} and IK_r
receptors. They can therefore be expected to manifest fewer side-effects than
15 compounds which do not discriminate in their binding affinity between such receptors.
In particular these compounds have lower effects on the IK_r receptors and there is a
separation of the desired effect from side effects such as cardiac effects.

By virtue of their potent human 5-HT_{2A} receptor antagonist activity, the
compounds of the present invention are effective in the treatment of neurological
20 conditions including sleep disorders such as insomnia, psychotic disorders such as
schizophrenia, and also depression, anxiety, panic disorder, obsessive-compulsive
disorder, pain, eating disorders such as anorexia nervosa, and dependency or acute
toxicity associated with narcotic agents such as LSD or MDMA; and moreover are
beneficial in controlling the extrapyramidal symptoms associated with the
25 administration of neuroleptic agents. They may further be effective in the lowering of
intraocular pressure, and may also be effective in treating menopausal symptoms, in
particular hot flushes (see Waldinger et al, *Maturitas*, 2000, 36, 165-8).


Various classes of compounds containing *inter alia* a sulphonyl moiety are
described in WO 00/43362, WO 96/35666, EP-A-0261688, EP-0304888, and US
30 Patents 4,218,455 and 4,128,552, DE-A-3901735 and Fletcher *et al*, *J. Med. Chem.*,
2002, 45, 492-503. None of these publications, however, discloses or suggests the
particular class of compounds provided by the present invention.

- 2 -

The compounds according to the present invention are potent and selective 5-HT_{2A} receptor antagonists, typically having a human 5-HT_{2A} receptor binding affinity (K_i) of 100 nM or less, typically of 50 nM or less and preferably of 10 nM or less.

The compounds of the invention may possess at least a 10-fold selective affinity, suitably at least a 20-fold selective affinity and preferably at least a 50-fold selective affinity, for the human 5-HT_{2A} receptor relative to the human dopamine D₂ receptor. The compounds of this invention may possess at least a 10-fold selective affinity, suitably at least a 20-fold selective affinity and preferably at least a 50-fold selective affinity of the human 5-HT_{2A} receptor relative to the IKr. The compounds of this invention may possess at least a 10-fold selective affinity, suitably at least a 20-fold selective affinity and preferably at least a 50-fold selective affinity for the human 5-HT_{2A} receptor relative to the human 5-HT_{2c} receptor. Preferred compounds show selectivities of at least 100 fold relative to the human 5-HT_{2c} receptor.

The present invention provides a compound of formula I:



or a pharmaceutically acceptable salt thereof wherein:

Ar is phenyl, benzisothiazol-3-yl or benzthiophen-3-yl, each of which bears substituent groups R¹, R² and R³;

R¹ is hydrogen, fluorine, chlorine, bromine, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₂₋₆ alkenyloxy, C₂₋₆ alkynyloxy, or C₁₋₆ alkyl substituted by up to 5-fluorine atoms;

R² is hydrogen, fluorine, chlorine, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkyl substituted by up to 5 fluorine atoms or C₁₋₄ alkoxy substituted by up to 5 fluorine atoms;

R³ is hydrogen, fluorine, chlorine, methyl, methoxy, trifluoromethyl, difluoromethyl, trifluoromethoxy or difluoromethoxy;

- 3 -

Q¹ is hydrogen; fluorine; chlorine; bromine; C₁₋₆ alkyl; C₃₋₆ cycloalkyl; C₂₋₆ alkenyl; C₂₋₆ alkynyl; C₁₋₆ alkoxy; C₂₋₆ alkenyloxy; C₂₋₆ alkynyloxy; C₁₋₆ alkyl substituted by up to 5-fluorine atoms; nitrile; COQ⁴ or CO₂Q⁴ where Q⁴ is hydrogen or C₁₋₆ alkyl; NQ⁵Q⁶, CONQ⁵Q⁶ or SO₂NQ⁵Q⁶ where Q⁵ is hydrogen or C₁₋₆ alkyl and Q⁶ is hydrogen or C₁₋₆ alkyl or Q⁵ and Q⁶ are joined to form either a 4-7 membered heterocyclic ring which may also contain one oxygen or one further nitrogen ring atom, which heterocyclic ring may optionally be substituted by up to 3 fluorine atoms or by CF₃, methyl, ethyl or hydroxyl; hydroxyl; nitro; SOQ⁷ or SO₂Q⁷ where Q⁷ is C₁₋₄ alkyl; NQ⁸COQ⁹, NQ⁸CO₂Q⁹ or NQ⁸SO₂Q⁹ where Q⁸ is hydrogen or C₁₋₄alkyl and Q⁹ is hydrogen or C₁₋₄alkyl or is joined to Q⁸ to form a 5-7 membered ring; a heteroaromatic ring of 5 ring atoms 1, 2, 3 or 4 of which may be nitrogen atoms or 1 or 2 of which are nitrogen atoms and 1 of which is an oxygen or sulfur atom or 1 of which is an oxygen or sulfur atom, which heteroaromatic ring optionally being substituted by methyl, ethyl or hydroxyl; or a heteroaromatic ring of 6 ring atoms containing 1 or 2 nitrogen ring atoms or a phenyl group either of which is optionally substituted by 1 or 2 fluorine or chlorine atoms or C₁₋₄alkyl, C₁₋₄alkoxy or trifluoromethyl groups;

Q² is hydrogen, fluorine, chlorine, nitrile, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkyl substituted by up to 5 fluorine atoms, or C₁₋₄ alkoxy substituted by up to 5 fluorine atoms;

Q³ is hydrogen, fluorine, chlorine, methyl, methoxy, trifluoromethyl, difluoromethyl, trifluoromethoxy or difluoromethoxy;

or Q² and Q³ are joined to form the residue of a 5, 6 or 7 membered carbocyclic ring;

R⁴ is H or C₁₋₄ alkyl,

m is 0 or 1;

n is 0, 1 or 2; and

W is CH₂, CHF, CH(OH) or CO.

In a subset of the compounds of formula I, R⁴ is H, m is 1, n is 0, W is CH₂, Ar is phenyl bearing the substituent groups R¹, R² and R³, and heterocyclic rings represented by NQ⁵Q⁶ are optionally substituted by methyl, ethyl or hydroxyl.

- 4 -

Suitable C₁₋₆ alkyl groups can be straight or branched. Hence such groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, secbutyl, and straight and branched pentyl and hexyl groups.

Favoured C₁₋₆ alkyl groups include methyl, ethyl, n-propyl, and the like.

5 A preferred C₁₋₆ alkyl group is the methyl group.

Suitable and favoured alkenyl and alkynyl groups are analogous to the suitable and favoured alkyl groups.

10 The expression "C₃₋₆cycloalkyl" as used herein refers to nonaromatic monocyclic hydrocarbon ring systems comprising from 3 to 6 ring atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclohexenyl.

For use in medicine, the compounds of formula I may be in the form of pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds of formula I or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention
15 include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, benzenesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.

20 Alternatively, where the compound of the invention carries an acidic moiety, the compound of formula I may exist as a zwitterion, or a pharmaceutically acceptable salt may be formed by neutralisation of said acidic moiety with a suitable base. Examples of pharmaceutically acceptable salts thus formed include alkali metal salts such as sodium or potassium salts; ammonium salts; alkaline earth metal salts such as calcium
25 or magnesium salts; and salts formed with suitable organic bases, such as amine salts (including pyridinium salts) and quaternary ammonium salts. The compounds of formula I are typically in the form of the free base, the hydrochloride salt or the methanesulfonate salt.

30 When the compounds according to the invention have one or more asymmetric centres, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist

- 5 -

as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.

In the compounds of formula I, R^4 represents H or C_{1-4} alkyl (such as methyl, ethyl or propyl), preferably H or methyl, and most preferably H.

5 n represents 0, 1 or 2, preferably 0 or 1, and most preferably 0.

m represents 0 or 1, typically 1 except when Ar represents a benzisothiazole or benzthiophene residue, in which case n and m are preferably both 0.

W represents CH_2 , CHF, $CH(OH)$ or CO, preferably CH_2 , CHF or CO. In a particular embodiment, $m=1$, W represents CH_2 , $n=0$ and R^4 is H.

10 Q^1 is preferably located para to the SO_2 group. Preferred identities for Q^1 include H, F, Cl, Br, CN, carboxamide, 5-membered heteroaryl and NQ^5Q^6 where Q^5 and Q^6 preferably complete a heterocyclic ring as defined previously. Examples of 5-membered heteroaryl rings represented by Q^1 include pyrrole, pyrazole, imidazole, triazole, tetrazole, oxazole and thiazole. Such rings may be bonded through carbon or
15 alternatively, in the case of pyrrole, pyrazole, imidazole, triazole and tetrazole, through nitrogen. Examples of heterocyclic groups represented by NQ^5Q^6 include azetidiny, pyrrolidinyl, piperidinyl, morpholinyl, 4-trifluoromethylpiperidin-1-yl and 4,4-difluoropiperdin-1-yl.

20 Q^2 is preferably H, F, Cl, CF_3 , methyl or methoxy, especially H, F or Cl, and is most preferably H or F.

Q^3 is preferably H or F, most preferably H.


R^1 is preferably attached in the 4-position when Ar represents a phenyl residue. Preferred identities for R^1 include H, F, Cl, Br, C_{1-6} alkyl (such as methyl), methoxy and CF_3 , in particular H, F, methyl and CF_3 .

25 R^2 is preferably attached in the 2-position when Ar represents a phenyl residue. Preferred identities for R^2 include H, F, Cl, C_{1-4} alkyl (such as methyl) and CF_3 , in particular H, F, methyl and CF_3 .

R^3 is preferably H or F, most preferably H.

Certain favoured compounds of the invention include those of formula (II):

- 6 -



and pharmaceutically acceptable salts thereof wherein:

R_1' is hydrogen, fluorine, chlorine, methyl, trifluoromethyl or methoxy;

5 R_2' is hydrogen, fluorine or chlorine;

R_3' is hydrogen or fluorine;

Q_1' is hydrogen, fluorine, chlorine, bromine, methyl, trifluoromethyl, methoxy, carboxamide, nitrile, or 1,2,3-triazolyl;


Q_2' is hydrogen, fluorine or chlorine;

10 Q_3' is hydrogen or fluorine.

In certain preferred compounds of formula (II) R_1' is hydrogen or fluorine, R_2' is hydrogen or fluorine and R_3' is hydrogen.

In certain preferred compounds of formula (II) Q_1' is at the 4-position and is hydrogen, fluorine, carboxamide, nitrile or 1,2,3-triazolyl, Q_2' is hydrogen or fluorine
15 and Q_3' is hydrogen.

A preferred subset of the compounds of the invention comprises the compounds of formula IIA:



(IIA)

20 and pharmaceutically acceptable salts thereof;

wherein R^{13} represents H and R^{14} represents H, F or OH, or R^{13} and R^{14} together represent keto;

and Q^1 , Q^2 , R^1 , R^2 and R^4 have the same meanings and preferred identities as before.

- 7 -

Within this embodiment, R¹ and R² are very suitably independently selected from H and F.

Within this embodiment, Q² is preferably H or F.

Within this embodiment, preferred identities for Q¹ include H, F, Cl, Br, CN, CONH₂, morpholin-1-yl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, pyrazol-1-yl, imidazole-1-yl, pyrrol-1-yl; 1-methylpyrazol-5-yl, 1-methylimidazol-2-yl, 2-methyltetrazol-5-yl, oxazol-2-yl, thiazol-2-yl, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, 4,4-difluoropiperidin-1-yl and 4-(trifluoromethyl)piperidin-1-yl.

Specific compounds of this invention include those compounds exemplified hereinafter and their pharmaceutically acceptable salts.

The compounds of the present invention have an activity as antagonists of the human 5-HT_{2A} receptor and hence find use in the treatment or prevention of disorders mediated by 5-HT_{2A} receptor activity.

The invention also provides pharmaceutical compositions comprising one or more compounds of this invention and a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. The principal active ingredient typically is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate and dicalcium phosphate, or gums, dispersing agents, suspending agents or surfactants such as sorbitan monooleate and polyethylene glycol, and other pharmaceutical diluents, e.g. water, to form a homogeneous preformulation composition containing a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from

- 8 -

1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient.

Tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter
5 being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with
10 such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, liquid- or gel-filled capsules, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil or coconut
15 oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, poly(ethylene glycol), poly(vinylpyrrolidone) or gelatin.

The present invention also provides a compound of formula I or a
20 pharmaceutically acceptable salt thereof for use in a method of treatment of the human body. Preferably the treatment is for a condition mediated by 5-HT_{2A} receptor activity.

The present invention further provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for
25 treating or preventing a condition mediated by 5-HT_{2A} receptor activity.

Also disclosed is a method of treatment of a subject suffering from or prone to a condition mediated by 5-HT_{2A} receptor activity which comprises administering to that subject an effective amount of a compound according to formula I or a pharmaceutically acceptable salt thereof.

30 In one aspect of the invention, the condition mediated by 5-HT_{2A} receptor activity is sleep disorder, in particular insomnia. In a further aspect of the invention, the condition mediated by 5-HT_{2A} receptor activity is selected from psychotic


- 9 -

disorders (such as schizophrenia), depression, anxiety, panic disorder, obsessive-compulsive disorder, pain, eating disorders (such as anorexia nervosa), dependency or acute toxicity associated with narcotic agents such as LSD or MDMA, and hot flushes associated with the menopause.


5 In the treatment envisaged herein, for example of insomnia or schizophrenia, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day but preferably once per day, for example before going to bed.

10 If desired, the compounds according to this invention may be co-administered with another sleep inducing or anti-schizophrenic or anxiolytic medicament. Such co-administration may be desirable where a patient is already established on sleep inducing or anti-schizophrenic or anxiolytic treatment regime involving other conventional medicaments.

15 The compounds of the formula (I) may be prepared by the reaction of the compounds of the formulae (III) and (IV):



(III)




(IV)

20 where X is a leaving group (especially halide, such as Br) and all other variables have the same meanings as before. The reaction takes place under conventional reaction conditions for alkylation, e.g. using a solvent such as tetrahydrofuran or acetonitrile at a temperature such as 80°C to 90°C in the presence of a base such as K₂CO₃, AgO or CsCO₃. A catalytic quantity of NaI may be employed in the conventional manner.

25 Alternatively, compounds of formula (III) may be reductively alkylated with compounds of formula (IVA):


- 10 -



(IVA)

where Ar, m, n, W and R⁴ are as defined previously (but W is preferably CH₂). The reaction takes place in ethanol in the presence of sodium borohydride and titanium tetraisopropoxide.


Compounds of formula (III) may alternatively be reacted with epoxides (IVB):



(IVB)

where Ar is as defined previously to provide compounds of formula (I) wherein R⁴ is H, n is 0, m is 1 and W is CH(OH).

The compound of formula (III) may be generated in situ by removal of a protecting group from a compound of the formula (Va)




wherein Prt is a protecting group, for example a t-butoxycarbonyl group which can be removed by treatment with trifluoroacetic acid or HCl/ethanol.


The compounds of formula (Va) can be prepared from the corresponding compounds of the formula (Vb) by reaction with a strong base such as nBuLi and a fluorinating agent such as (PhSO₂)₂NF. This reaction will normally take place in a solvent such as tetrahydrofuran at a temperature of -78°C to 25°C.

The compounds (Vb) may be obtained by reaction of a thiol of formula (VI) with a piperidine of formula (VII) and oxidation of the resulting thioether:

- 11 -



(VI)



(VII)

where Y is a leaving group (preferably mesylate or a similar sulphonate ester) and all other variables are as defined previously. Formation of the thioether takes place in refluxing acetonitrile in the presence of a base such as K_2CO_3 and the oxidation may be effected by conventional means (e.g. using m-chloroperoxybenzoic acid or by refluxing with oxone and wet alumina in chloroform). Details of these procedures are provided in WO 00/43362 and *J. Med. Chem.*, 2002, **45**, 492-503.

If desired, the aforementioned oxidation may be carried out in two stages via the corresponding sulfoxide intermediate (e.g. by using the oxone method at ambient temperature as the first step). The sulfoxide may be fluorinated in the 4-position of the piperidine ring by treatment with a fluorinating agent such as diethylaminosulfur trifluoride (DAST) (typically in the presence of antimony trifluoride in an inert solvent such as dichloromethane at ambient temperature). Treatment of the resulting compound with an oxidizing agent such as metachloroperoxybenzoic acid (for example in an inert solvent such as dichloromethane at ambient temperature) then provides compounds (Va).

The compounds of the formula (I) may also be prepared by the fluorination of the corresponding compound which possesses a hydrogen atom instead of the fluorine atom of the compound of formula (I). This may be effected using a fluorinating agent such as $(PhSO_2)_2NF$ and a strong base such as NaHMDS at $-78^\circ C$ to $25^\circ C$ in an inert solvent such as tetrahydrofuran.

Where they are not commercially available, the starting materials of formula VI and VII may be prepared by procedures analogous to those described in the accompanying Examples, or by standard methods well known from the art.

It will be appreciated that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further desired compound of formula I using techniques known from the art. For example, a compound of formula I initially obtained wherein Q^1 represents bromo

- 12 -

may be converted into the corresponding compound of formula I wherein Q¹ represents cyano by treatment with copper(I) cyanide in the presence of 1-methyl-2-pyrrolidinone (NMP), or with zinc cyanide in the presence of tetrakis(triphenylphosphine)palladium(0). The resulting compound of formula I wherein Q¹ represents cyano thereby obtained may in turn be converted into the corresponding compound of formula I wherein Q¹ represents carboxamido by heating in mineral acid, e.g. 85% sulphuric acid at 100°C, or by treatment with potassium trimethylsilanolate, typically in tetrahydrofuran at reflux. Alternatively, a compound of formula I initially obtained wherein Q¹ represents bromo may be converted directly into the corresponding compound of formula I wherein Q¹ represents carboxamido by heating under a carbon monoxide atmosphere in the presence of 1,1,1,3,3,3-hexamethyldisilazane, diisopropylamine, palladium(II) acetate and 1,3-bis(diphenylphosphino)propane. Where, for example, Q¹ in the compounds of formula I represents an optionally substituted N-linked heterocyclic moiety, e.g. imidazol-1-yl, pyrazol-1-yl, 1,2,3-triazol-1-yl, 1,2,4-triazol-1-yl, pyrrolidin-1-yl, piperidin-1-yl or azetidin-1-yl, these compounds may be prepared by treating the corresponding compound of formula I wherein Q¹ represents fluoro with the appropriate optionally substituted N-heterocycle, typically with heating in DMSO. Where, for example, Q¹ in the compounds of formula I represents an optionally substituted C-linked five-membered heteroaromatic ring, e.g. 2-methyltetrazol-5-yl or 1-methyl-1,2,4-triazol-5-yl, these compounds may be prepared by reacting the corresponding compound of formula I wherein Q¹ represents bromo with a tributylstannyl derivative of the appropriate heteroaromatic compound, e.g. 2-methyl-5-tributylstannyltetrazole or 1-methyl-5-tributylstannyl-1,2,4-triazole, in the presence of a transition metal catalyst such as tetrakis(triphenylphosphine)palladium(0), typically with heating in a solvent such as *N,N*-dimethylformamide.

Similarly, compounds wherein W is CO may be reduced to provide corresponding compounds wherein W is CH(OH). These in turn may be treated with DAST to provide compounds wherein W is CHF.

Where the above-described processes for the preparation of the compounds of use in the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The

- 13 -

compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as di-*p*-toluoyl-D-tartaric acid and/or di-*p*-toluoyl-L-tartaric acid, followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art. Compounds were tested for their binding to the 5-HT_{2A} receptor and to other receptors such as 5-HT_{2C} and 5-HT_{1A} using the methodology described in Fletcher *et al*, *J. Med. Chem.*, 2002, 45, 492-503.

EXAMPLE 1

4-(4-Bromophenylsulfonyl)-1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoropiperidine

To a suspension of wet alumina (10% water, 13 g) in chloroform (60 mL), was added, N-BOC 4-(4-bromophenylthio)piperidine (prepared according to Fletcher, S. R. *et al.*, *J. Med. Chem.* 2002, 45, 492-503), followed by Oxone[®] (24 g). The reaction was stirred for 3 h, filtered and chromatographed on silica eluting with 50% EtOAc/isohexane to obtain N-BOC 4-(4-bromophenylsulfinyl)piperidine (3.5 g, 69%): δ_H (400 MHz, CDCl₃) 1.44 (9H, s), 1.55-1.8 (4H, m), 2.6-2.75 (3H, m), 4.25 (2H, m), 7.47 (2H, d), 7.67 (2H, d).

N-BOC 4-(4-bromophenylsulfinyl)piperidine (3.17 g, 8.5 mmol) was dissolved in dichloromethane (50 mL) and antimony trichloride (194 mg, 0.85 mmol) was added, followed by diethylaminosulfur trifluoride (2.8 mL, 0.022 mol). The reaction

- 14 -

mixture was stirred for 16 h at room temperature, then quenched with cold, saturated sodium bicarbonate solution and the product extracted into ethyl acetate. The organic layer was washed with brine, dried over MgSO_4 and evaporated. The residue was dissolved in dichloromethane (50 mL) and added to a solution of *m*CPBA (50-55%;
5 7.3 g, 0.021 mol) in dichloromethane (30 mL), which had been previously dried over MgSO_4 and filtered. The reaction mixture was stirred at 25°C for 2 h, then quenched with saturated sodium metabisulfite. The product was extracted into dichloromethane, and the organic layer washed with saturated sodium bicarbonate solution and brine. After drying over MgSO_4 , the solvent was removed *in vacuo* and the residue
10 chromatographed on silica, eluting with 10% EtOAc/isohexane to obtain N-BOC 4-(4-bromophenylsulfonyl)-4-fluoropiperidine as a white solid (2.3 g, 70%): δ_{H} (360 MHz, CDCl_3) 1.46 (9H, s), 1.9 (2H, m), 2.02-2.3 (2H, m), 2.9 (2H, m), 4.2 (2H, m), 7.8 (4H, dd).

N-BOC 4-(4-Bromophenylsulfonyl)-4-fluoropiperidine (2.3 g, 5.5 mmol) was
15 dissolved in 6 N HCl (30 mL) and ethanol was added until the cloudy solution became clear (ca. 20 mL). The reaction mixture was heated to 85°C and stirred at that temperature for 16 h. The reaction mixture was cooled, the ethanol evaporated and the acidic solution made basic by the addition of 5 N NaOH. The product was extracted into EtOAc and the organic layer washed with brine and dried over MgSO_4 . 4-(4-Bromophenylsulfonyl)-4-fluoropiperidine hydrogen chloride was obtained as a white
20 solid after evaporation of the solvent *in vacuo* (1.4 g, 80%): δ_{H} (360 MHz, CDCl_3) 1.84 (2H, dt), 2.04-2.22 (2H, m), 2.82 (2H, dt), 3.09 (2H, dt), 7.75 (4H, m). m/z (ES^+) 322, 324 ($\text{M}+1$).

4-(4-Bromophenylsulfonyl)-4-fluoropiperidine hydrogen chloride (1.4 g,
25 4mmol) was dissolved in acetonitrile and potassium carbonate (1.4 g, 0.01mol) was added, followed by 2,4-difluorophenethyl bromide (prepared as described in WO 00/43362, 1.3 g, 6 mmol). The reaction was heated to reflux for 16 h. After cooling, the reaction mixture was partitioned between EtOAc and water and the organic layer washed with brine, dried over MgSO_4 and evaporated. The residue was
30 chromatographed on silica eluting with 30% EtOAc/isohexane to obtain the title compound as a white solid (0.950 g, 51%): δ_{H} (360 MHz, CDCl_3) 1.86 (2H, t), 2.22-

- 15 -

2.39 (4H, m), 2.57 (2H, t), 2.76 (2H, t), 2.93 (2H, m), 6.76 (2H, m), 7.13 (1H, m), 7.74 (4H, m). m/z (ES^+) 462, 464 ($M+1$).

EXAMPLE 2

5

1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-(4-fluorophenylsulfonyl)piperidine

Method 1

Sodium bis(trimethylsilyl)amide (1.0 M in THF; 0.3 mL, 0.3 mmol) was added dropwise to a stirred solution of 1-[2-(2,4-difluorophenyl)ethyl]-4-(4-fluorophenylsulfonyl)piperidine (95.8 mg, 0.25 mmol) (prepared according to Fletcher, S. R. *et al.*, *J. Med. Chem.* 2002, 45, 492-503) in THF (0.5 mL) at $-78^{\circ}C$. The solution was warmed to $0^{\circ}C$, stirred for 5 min, then re-cooled to $-78^{\circ}C$. A solution of N-fluorobis(phenylsulfonyl)amine (80.8 mg, 0.38 mmol) in THF (0.25 mL) was added and the mixture was allowed to reach ambient temperature, then stirred for 15 min. The reaction was quenched by addition of saturated aqueous NH_4Cl (1 mL), then partitioned between water (20 mL) and EtOAc (20 mL). The organic fraction was dried over Na_2SO_4 , filtered and concentrated *in vacuo* and the crude material purified by column chromatography (silica, 30% EtOAc/isohexane) to afford the title compound as a white solid (19 mg): δ_H (500 MHz, DMSO) 1.79-1.83 (2H, m), 2.20-2.19 (4H, m), 2.52-2.55 (2H, m), 2.73-2.76 (2H, m), 2.95-2.97 (2H, m), 7.00-7.04 (1H, m), 7.14-7.19 (1H, m), 7.36-7.41 (1H, m), 7.56-7.61 (2H, m), 7.96-7.99 (2H, m). m/z (ES^+) 402 (100%, $[MH]^+$).

20

Method 2

n-Butyllithium (1.6 M in isohexanes; 13 mL, 20.8 mmol) was added dropwise to a stirred solution of N-BOC 4-(4-fluorophenylsulfonyl)piperidine (6 g, 17.4 mmol) in THF (70 mL) at $-78^{\circ}C$. After 1 h, a solution of N-fluorobis(phenylsulfonyl)amine (6.04 g, 19 mmol) in THF (17 mL) was added dropwise and the mixture was brought to ambient temperature, stirred for 1 h, then quenched by the addition of water (1 mL) and partitioned between saturated aqueous NH_4Cl (80 mL) and EtOAc (80 mL). The organic fraction was washed with brine (30 mL), dried over Na_2SO_4 , filtered and concentrated *in vacuo*. Purification by column chromatography (silica, 20%

25

30

- 16 -

EtOAc/isohexane) afforded N-BOC 4-fluoro-4-(4-fluorophenylsulfonyl)piperidine as an off-white solid (4.8 g): δ_H (360 MHz, $CDCl_3$) 1.46 (9H, s), 1.80-1.95 (2H, m), 2.05-2.30 (2H, m), 2.90-3.00 (2H, m), 4.12-4.22 (2H, m), 7.28 (2H, t, J 8.5 Hz), 7.93-7.96 (2H, m). m/z (ES^+) 261 [(M-BOC)H] $^+$.

5 N-BOC 4-fluoro-4-(4-fluorophenylsulfonyl)piperidine (2 g, 5.5 mmol) was suspended in a mixture of EtOH (50 mL) and 6 N HCl (25 mL) and the mixture heated to 80°C until dissolution occurred. The solution was then concentrated *in vacuo* and the resulting residue washed with a 10:1 mixture of Et₂O and EtOAc (50 mL) to afford 4-fluoro-4-(4-fluorophenylsulfonyl)piperidine hydrogen chloride as a white solid.

10 4-Fluoro-4-(4-fluorophenylsulfonyl)piperidine hydrogen chloride was alkylated with difluorophenethyl bromide as described in Example 1 and recrystallised from 50% EtOAc/isohexane to afford the title compound, analytically consistent with the previous data.

15 EXAMPLE 3

4-({1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoropiperidin-4-yl}sulfonyl)benzonitrile

Method 1

20 4-(4-Bromophenylsulfonyl)-1-[2-(2,4-difluorophenyl)ethyl]-4-fluoropiperidine (0.350 g, 0.758 mmol) was dissolved in anhydrous DMF (10 mL) and zinc cyanide (0.090 g, 0.758 mmol) added. The solution was degassed with nitrogen for 5 minutes and tetrakis(triphenylphosphine) palladium (0) (100 mg) added. The reaction was heated to 85°C for 2 h. Another 100 mg of tetrakis(triphenylphosphine)palladium (0) was added followed by another 100mg after 0.5 h. Another 100 mg of palladium
25 catalyst was then added and the reaction heated at 95°C for 72 h. The reaction mixture was partitioned between EtOAc and water, the organic layer collected and washed with water (x 3) and brine, then dried over MgSO₄. The solvent was removed *in vacuo* and the residue chromatographed on silica eluting with 10-25%
EtOAc/isohexane to obtain a solid that was recrystallised from EtOAc/isohexane to
30 give the title compound as a white solid (0.153 g): δ_H (400MHz, $CDCl_3$) 1.87 (2H, m), 2.33 (4H, m), 2.58 (2H, m), 2.76 (2H, m), 2.94 (2H, m), 6.78 (2H, m), 7.13 (1H, m), 7.88 (2H, d), 8.04 (2H, d).

Method 2

1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-(4-fluorophenylsulfonyl)piperidine (25 mg, 0.062 mmol), sodium cyanide (20 mg, 0.41 mmol) and DMSO (0.5 mL) were combined and heated to 120°C for 18 h. On cooling, water (5 mL) was added and the resulting precipitate isolated by filtration. The residue was washed with water (10 mL) and dried by a continuous stream of air to afford the title compound (10 mg), analytically consistent with the previous data.

10 Method 3

N-BOC 4-(4-bromophenylsulfonyl)piperidine (25 g, 62 mmol) (prepared according to Fletcher, S. R. *et al.*, *J. Med. Chem.* 2002, **45**, 492-503), zinc cyanide (8.73 g, 74 mmol) and tetrakis(triphenylphosphine)palladium (0) (3.58 g, 3.1 mmol) were combined in N-methylpyrrolidine (250 mL) and the mixture heated at 160°C for 30 min. On cooling, the reaction mixture was partitioned between EtOAc (250 mL) and saturated aqueous NaHCO₃ (200 mL). The organic fraction was washed with water (2 x 150 mL) and brine (150 mL), dried over MgSO₄ and concentrated *in vacuo* to approximately 100 mL, at which point precipitation began to occur. Et₂O (500 mL) was added and the resulting precipitate was filtered off, washed with further Et₂O (200 mL) and dried in a vacuum oven to afford N-BOC 4-(piperidin-4-ylsulfonyl)benzonitrile (9.9 g). δ_H (500 MHz, DMSO) 1.30-1.40 (2H, m), 1.37 (9H, s), 1.80-1.85 (2H, m), 2.65-2.79 (2H, m), 3.60-3.68 (1H, m), 3.95-4.05 (2H, m), 8.04 (2H, d, *J* 8.5 Hz), 8.17 (2H, d, *J* 8.5 Hz).

n-Butyllithium (1.6 M in isohexanes; 18.3 mL, 29 mmol) was added to a stirred solution of 2,2,6,6-tetramethylpiperidine (5.4 mL, 32 mmol) in THF (50 mL) at -78°C followed, after 5 min, by a solution of N-BOC 4-(piperidin-4-ylsulfonyl)benzonitrile (9.9 g, 29.3 mmol) in THF (100 mL). The solution was warmed to -10°C and stirred for 90 min prior to addition of a solution of N-fluorobis(phenylsulfonyl)amine (10.1 g, 32 mmol) in THF (40 mL). The reaction mixture was warmed to ambient temperature, stirred for 30 min, then partitioned between EtOAc (150 mL) and saturated aqueous NH₄Cl (150 mL). The organic fraction was dried over MgSO₄, filtered and concentrated *in vacuo* and the crude

- 18 -

product purified by column chromatography (silica, 20% EtOAc/isohexane) to afford N-BOC 4-(4-fluoropiperidin-4-ylsulfonyl)benzonitrile (6 g): δ_H (500 MHz, DMSO) 1.41 (9H, s), 1.82-1.90 (2H, m), 1.96-1.11 (2H, m), 2.82-2.93 (2H, m), 3.95-4.05 (2H, m), 8.09 (2H, d, J 8.2 Hz), 8.22 (2H, d, J 8.5 Hz).

- 5 N-BOC 4-(4-fluoropiperidin-4-ylsulfonyl)benzonitrile was deprotected and alkylated by the methods described in Examples 2 and 1 respectively to afford the title compound, analytically consistent with the previous data.

EXAMPLE 4

10

4-({1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoropiperidin-4-yl} sulfonyl)benzamide

- Water (0.5 mL), K_2CO_3 (9 mg, 0.065 mmol) and aqueous hydrogen peroxide (*circa* 50%, 0.05 mL, *circa* 0.7 mmol) were added sequentially to a vigorously stirred solution of 4-({1-[2-(2,4-difluorophenyl)ethyl]-4-fluoropiperidin-4-yl} sulfonyl)benzonitrile (53 mg, 0.13 mmol) in DMSO (1 mL). After 30 min, the reaction mixture was partitioned between EtOAc (20 mL) and brine (20 mL) and the organic fraction dried over Na_2SO_4 , filtered and concentrated *in vacuo*. Purification by column chromatography (silica, 10% EtOH/EtOAc) afforded the title product as a white solid (8 mg): δ_H (500 MHz, DMSO) 1.75-1.85 (2H, m), 2.02-2.20 (4H, m), 2.50-2.55 (2H, m), 2.70-2.78 (2H, m), 2.91-2.99 (2H, m), 6.98-7.02 (1H, m), 7.11-7.18 (1H, m), 7.31-7.41 (1H, m), 7.81 (1H, s), 7.97 (2H, d J 8.4 Hz), 8.13 (2H, d J 8.3 Hz), 8.25 (1H, s). m/z (ES^+) 427 [MH]⁺
- 15
20

EXAMPLE 5

25

4-({4-Fluoro-1-[2-(2-fluorophenyl)ethyl]piperidin-4-yl} sulfonyl)benzamide

- A solution of N-BOC 4-(4-fluoropiperidin-4-ylsulfonyl)benzonitrile (1 g, 2.7 mmol) and potassium trimethylsilanolate (346 mg, 2.7 mmol) in toluene (12 mL) was heated to reflux for 2 h. On cooling, the reaction mixture was partitioned between saturated aqueous NH_4Cl (20 mL) and EtOAc (20 mL) and the aqueous portion extracted with further EtOAc (2 x 20 mL). The combined organic fractions were dried over $MgSO_4$, filtered and concentrated and the residue purified by column
- 30

- 19 -

chromatography (silica, 30-80% EtOAc/isohexane) to afford N-BOC 4-(4-fluoropiperidin-4-ylsulfonyl)benzamide (350 mg): δ_H (500 MHz, DMSO) 1.47 (9H, s), 1.82-1.94 (2H, m), 2.12-2.28 (2H, m), 2.89-2.99 (2H, m), 4.10-4.20 (2H, m), 5.90-6.00 (1H, m), 6.18-6.28 (1H, m), 8.02 (4H, s).

5 N-BOC 4-(4-fluoropiperidin-4-ylsulfonyl)benzamide was deprotected and alkylated by the methods described in Examples 2 and 1 respectively to afford the title compound as a white solid. δ_H (500 MHz, DMSO) 1.78-1.83 (2H, m), 2.05-2.20 (4H, m), 2.53-2.56 (2H, m), 2.74-2.77 (2H, m), 2.96-2.97 (2H, m), 7.10-7.14 (2H, m), 7.22-7.26 (1H, m), 7.30-7.34 (1H, m), 7.70 (1H, s), 7.97 (2H, d J 8.3 Hz), 8.12-8.14 (2H, m), 8.25 (1H, s). m/z (ES⁺) 409 [MH]⁺.

10

The following compounds (Examples 6-22) were prepared using analogous methods to Examples 1-5:

15 4-Fluoro-4-(4-fluorophenylsulfonyl)-1-[2-(4-fluorophenyl)ethyl]piperidine
 m/z (ES⁺) 384 [MH]⁺.

4-Fluoro-4-(4-fluorophenylsulfonyl)-1-[2-(2-fluorophenyl)ethyl]piperidine
 m/z (ES⁺) 384 [MH]⁺.

20 4-Fluoro-4-(4-fluorophenylsulfonyl)-1-(2-phenylethyl)piperidine
 m/z (ES⁺) 366 [MH]⁺.

25 4-({4-Fluoro-1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}sulfonyl)benzonitrile
 m/z (ES⁺) 391 [MH]⁺.

4-({4-Fluoro-1-[2-(2-fluorophenyl)ethyl]piperidin-4-yl}sulfonyl)benzonitrile
 m/z (ES⁺) 391 [MH]⁺.

30 4-({4-Fluoro-1-(2-phenylethyl)piperidin-4-yl}sulfonyl)benzonitrile
 m/z (ES⁺) 373 [MH]⁺.

- 20 -

4-({4-Fluoro-1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}sulfonyl)benzamide

m/z (ES⁺) 409 [MH]⁺.

4-{[4-Fluoro-1-(2-phenylethyl)piperidin-4-ylsulfonyl]benzamide

5 m/z (ES⁺) 391 [MH]⁺.

1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-(phenylsulfonyl)piperidine

m/z (ES⁺) 384 [MH]⁺.

10 4-Fluoro-1-(2-(2-fluorophenyl)ethyl)-4-(phenylsulfonyl)piperidine

m/z (ES⁺) 366 [MH]⁺.

4-Fluoro-1-(2-(4-fluorophenyl)ethyl)-4-(phenylsulfonyl)piperidine

m/z (ES⁺) 366 [MH]⁺.

15

4-Fluoro-1-(2-phenylethyl)-4-(phenylsulfonyl)piperidine

m/z (ES⁺) 348 [MH]⁺.

1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-(2-fluorophenylsulfonyl)piperidine

20 m/z (ES⁺) 402 [MH]⁺.

1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-(3-fluorophenylsulfonyl)piperidine

m/z (ES⁺) 402 [MH]⁺.

25 4-(4-Chlorophenylsulfonyl)-1-[2-(2,4-difluorophenyl)ethyl]-4-fluoropiperidine

m/z (ES⁺) 419 [MH]⁺.

4-({4-Fluoro-1-[(6-fluoro-1,2-benzisothiazol-3-yl)methyl]piperidin-4-yl}sulfonyl)benzonitrile

30 m/z (ES⁺) 434 [MH]⁺.

- 21 -

6-Fluoro-3-({4-fluoro-4-[(4-fluorophenyl)sulfonyl]piperidin-1-yl}methyl)-1,2-benzisothiazole

m/z (ES^+) 427 [MH] $^+$.

5

EXAMPLE 23

4-[4-({1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoropiperidin-4-yl}sulfonyl)phenyl]morpholine

4-(4-Bromophenylsulfonyl)-1-[2-(2,4-difluorophenyl)ethyl]-4-fluoropiperidine
10 (25 mg, 0.054 mmol) was dissolved in anhydrous toluene (1.5 mL). Morpholine (0.01 mL, 0.108 mmol) and *rac*-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (2.7 mg; 5 mol%) was added. The solution was degassed with nitrogen for 5 minutes and palladium acetate (1.1 mg; 2 mol%) and cesium carbonate (26 mg, 0.082 mmol) added. The reaction was heated to 90°C for 16 h. The reaction mixture was
15 partitioned between dichloromethane and water and the organic layer was collected and washed with water and brine, then dried over Na_2SO_4 . The solvent was removed *in vacuo* and the residue chromatographed on silica eluting with 70% EtOAc/isohexane to give the title compound as a white solid (16 mg): δ_H (400 MHz, DMSO) 1.75 (2H, m), 1.97 (2H, m), 2.09 (2H, m), 2.71 (2H, m), 2.92 (2H, m), 3.34
20 (4H, m), 3.72 (4H, m), 6.97 (1H, m), 7.08 (3H, m), 7.35 (1H, m), 7.61 (2H, m). m/z (ES^+) 469 [MH] $^+$.

EXAMPLE 24

25 1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-[4-(pyrrolidin-1-yl)phenylsulfonyl]piperidine

4-(4-Fluorophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-4-fluoropiperidine (100 mg, 2.44 mmol) was dissolved in DMSO (5 ml). Pyrrolidine (0.61 mL, 7.32 mmol) was added and the resultant solution heated to 150°C in a
30 microwave reactor for 10 minutes. On cooling, the reaction mixture was partitioned between EtOAc (30 mL) and aqueous saturated $NaHCO_3$ (30 mL). The organic layer was washed with water, dried over Na_2SO_4 , filtered and concentrated *in vacuo* to give

- 22 -

the title compound as a white solid requiring no purification (102 mg): δ_H (400 MHz, DMSO) 1.75 (2H, m) 2.0 (4H, m) 2.1 (2H, m) 2.5 (2H, m) 2.7 (2H, m) 2.95 (2 H, m) 3.35 (4H, m) 6.7 (2H, d) 7.0 (1H, m) 7.15 (1H, m) 7.4 (1H, m) 7.6 (2H, d). m/z (ES^+) 453 [MH] $^+$.

5

The following compounds (Examples 25-31) were prepared using analogous methods to Examples 23-24:

10 1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-[4-(piperidin-1-yl)phenylsulfonyl]piperidine

m/z (ES^+) 467 [MH] $^+$.

15 1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-{4-[4-(trifluoromethyl)piperidin-1-yl]phenylsulfonyl}piperidine

m/z (ES^+) 535 [MH] $^+$.

20 4-[4-(Azetidin-1-yl)phenylsulfonyl]-1-[2-(2,4-difluorophenyl)ethyl]-4-fluoropiperidine

m/z (ES^+) 439 [MH] $^+$.

20

1-[2-(2,4-Difluorophenyl)ethyl]-4-[4-(4,4-difluoropiperidin-1-yl)phenylsulfonyl]-4-fluoropiperidine

m/z (ES^+) 503 [MH] $^+$.

25 1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-[4-([1,2,3]triazol-1-yl)phenylsulfonyl]piperidine

m/z (ES^+) 451 [MH] $^+$.

30 1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-[4-(pyrrol-1-yl)phenylsulfonyl]piperidine

m/z (ES^+) 449 [MH] $^+$.

- 23 -

1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-[4-(pyrazol-1-yl)phenylsulfonyl]piperidine
 m/z (ES^+) 450 [MH] $^+$.

5 The following compounds (Examples 32-35) were prepared from 4-(3,4-difluorophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-4-fluoropiperidine by an analogous method to Example 24.

1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-{[3-fluoro-4-(pyrazol-1-yl)phenyl]sulfonyl}piperidine
10 m/z (ES^+) 468 [MH] $^+$.

1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-{[3-fluoro-4-(imidazol-1-yl)phenyl]sulfonyl}piperidine
15 m/z (ES^+) 468 [MH] $^+$.

1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-{[3-fluoro-4-(1,2,3-triazol-1-yl)phenyl]sulfonyl}piperidine
20 m/z (ES^+) 469 [MH] $^+$.

1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-{[3-fluoro-4-(1,2,4-triazol-1-yl)phenyl]sulfonyl}piperidine
25 m/z (ES^+) 469 [MH] $^+$.

EXAMPLE 36

25

1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-[4-(1,3-oxazol-2-yl)phenylsulfonyl]piperidine

4-(4-Bromophenylsulphonyl)-1-[2-(2,4-difluorophenyl)ethyl]-4-fluoropiperidine (50 mg, 0.108 mmol) and 2-(tributylstannyl)oxazole (0.04 mL, 0.119 mmol) were dissolved in anhydrous THF (0.25 mL) and the solution was degassed with nitrogen for 5 minutes prior to addition of bis(triphenylphosphine)palladium(II) chloride (3.8 mg, 5 mol%). The reaction mixture was heated at 80°C for 72 h, then

30

- 24 -

partitioned between DCM (20 mL) and water (20 mL) and the organic layer dried over Na₂SO₄, filtered and concentrated *in vacuo*. The resultant residue was diluted with DCM (0.5 mL) and passed through a SCX cartridge and the absorbed material washed with further DCM (10 mL). The product eluted on introduction of ammonia in MeOH (2M, 10 mL). The fractions were combined, the volatiles evaporated and the residue purified by column chromatography (silica, 65% EtOAc/isohexane) to give the title compound as a white solid (28 mg): δ_H (400 MHz, DMSO) 1.8 (2H, m) 2.1 (4H, m) 2.55 (2H, m) 2.7 (2H, m) 2.95 (2H, m) 7.0 (1H, m) 7.15 (1H, m) 7.4 (1H, m) 7.55 (1H, s) 8.05 (2H, d) 8.29 (2H, d) 8.35 (1H, s). m/z (ES⁺) 451 [MH]⁺.

10

The following compounds (Examples 37-40) were prepared using analogous methods to Example 36:

15 1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-[4-(1-methylpyrazol-5-yl)phenylsulfonyl]piperidine
 m/z (ES⁺) 464 [MH]⁺.

20 1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-[4-(1-methylimidazol-2-yl)phenylsulfonyl]piperidine
 m/z (ES⁺) 464 [MH]⁺.

25 1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-[4-(2-methyltetrazol-5-yl)phenylsulfonyl]piperidine
 m/z (ES⁺) 466 [MH]⁺.

1-[2-(2,4-Difluorophenyl)ethyl]-4-fluoro-4-[4-(1,3-thiazol-2-yl)phenylsulfonyl]piperidine
 m/z (ES⁺) 467 [MH]⁺.

EXAMPLE 41**4-[(2-Bromo-4-fluorophenyl)sulfonyl]-1-[2-(2,4-difluorophenyl)ethyl]-4-fluoropiperidine**

5 n-Butyllithium (1.6 N in isohexanes; 1.0 mL, 1.6 mmol) was added dropwise to a stirred solution of N-BOC 4-fluoro-4-(4-fluorophenylsulfonyl)piperidine (500 mg; 1.4 mmol) in diethyl ether (16 mL) at -78°C. After 1 h, 1,2-dibromotetrafluoroethane (0.54 g, 2.1 mmol) was added briskly and the mixture stirred for 5 minutes prior to warming to 0°C at which temperature it was stirred for a further 1.5 h. Saturated aqueous NH₄Cl (1 mL) was added and the mixture partitioned between water (20 mL) and EtOAc (20 mL). The organic portion was dried over Na₂SO₄, filtered and concentrated *in vacuo* to afford crude product which was deprotected and alkylated as described in Examples 2 and 1 respectively. The final material was washed with a 50% Et₂O/isohexane to afford the title compound as a white solid (117 mg): δ_H (400 MHz, DMSO) 1.75-1.90 (2H, m), 2.04-2.22 (4H, m), 2.50-2.55 (2H, m), 2.70-2.75 (2H, m), 2.95-3.00 (2H, m), 6.98-7.02 (1H, m), 7.12-7.18 (1H, m), 7.35-7.40 (1H, m), 7.58-7.62 (1H, m), 7.98-8.00 (1H, m), 8.10-8.13 (1H, m). m/z (ES⁺) 482, 480 [MH]⁺. The material also contained a 3.6% impurity of 1-[2-(2,4-difluorophenyl)ethyl]-4-fluoro-4-(4-fluorophenylsulfonyl)piperidine, consistent with the data presented in

10

15

20 Example 2.

EXAMPLE 42**(RS)-1-[2-(2,4-Difluorophenyl)-2-fluoroethyl]-4-fluoro-4-(phenylsulfonyl)piperidine**

25 4-Fluoro-4-(phenylsulfonyl)piperidine hydrogen chloride (300 mg, mmol) was treated with saturated aqueous sodium bicarbonate and the free base extracted into EtOAc. The organic layer was dried over MgSO₄ and the solvent removed *in vacuo* to yield 4-fluoro-4-(phenylsulfonyl)piperidine (187 mg) as a white solid.

30 2-(2, 4-Difluorophenyl)oxirane (0.17 ml, 1.08 mmol) was added to a solution of 4-fluoro-4-(phenylsulfonyl)piperidine (187 mg, 0.9 mmol) in DMSO (5 ml) and the resultant solution heated to 105°C for 10 hours. On cooling, the reaction solution was poured into a brine solution (10ml) and extracted into EtOAc. The organic layer was

- 26 -

washed with water (3 x 10 ml), dried over Na₂SO₄, filtered and concentrated. The resultant residue was purified by column chromatography (silica, 30%

EtOAc/isohexane) to give (*RS*)-1-(2,4-difluorophenyl)-2-[4-fluoro-4-

(phenylsulfonyl)piperidin-1-yl]ethanol as a white solid (108 mg): δ_H (400 MHz,

5 DMSO) 1.75 (2H, m) 2.05 (2H, m) 2.2 (2H, m) 2.5 (2H, m) 2.95 (2 H, m) 4.95 (1H, m) 5.39 (1H, d) 7.05 (1H, m) 7.15 (1H, m) 7.5 (1H, m) 7.72 (2H, m) 7.85 (3H, m). m/z (ES⁺) 399 [MH]⁺.

To a cooled (-78°C) solution of (*RS*)-1-(2,4-difluorophenyl)-2-[4-fluoro-4-(phenylsulfonyl)piperidin-1-yl]ethanol (40 mg, 0.10 mmol) in anhydrous DCM (0.5

10 ml) under a nitrogen atmosphere was added (diethylamino)sulfur trifluoride (0.02 ml, 0.15 mmol). The solution was stirred for 10 minutes at -78 °C, then allowed to warm to room temperature and left to stir for 2 h. The reaction was quenched with saturated aqueous sodium bicarbonate solution (20 ml) and extracted into EtOAc (3 x 20 ml).

The combined organic fractions were dried over Na₂SO₄, filtered and concentrated *in vacuo*. The resultant residue was purified by column chromatography (silica, 25% EtOAc/isohexane) to give the title compound as a white solid (29 mg): δ_H (400 MHz, DMSO) 1.8 (2H, m) 2.1 (2H, m) 2.2 (2H, m) 2.7 (2H, m) 2.95 (3 H, m) 5.8-5.9 (1H, ddd) 7.15 (1H, m) 7.25 (1H, m) 7.55 (1H, m) 7.72 (2H, m) 7.85 (3H, m). m/z (ES⁺) 402 [MH]⁺.

20

EXAMPLE 43

2-[4-Fluoro-4-(4-fluorophenylsulfonyl)piperidin-1-yl]-1-(4-fluorophenyl)ethanone

4-Fluoro-2'-bromoacetophenone (55 mg, 0.25 mmol) was added to a mixture of 4-fluoro-4-(4-fluorophenylsulfonyl)piperidine hydrogen chloride (60 mg, 0.23

25 mmol) and triethylamine (0.064 mL, 0.50 mmol) in MeCN (1.2 mL). The solution was stirred at ambient temperature for 4 h, then partitioned between water (20 mL) and EtOAc (20 mL). The organic portion was dried over Na₂SO₄, filtered and concentrated *in vacuo* affording crude material, which was purified by column

30 chromatography (silica, 50% EtOAc/isohexane) to yield the title compound as a white solid (30 mg): δ_H (500 MHz, DMSO) 1.95 (2H, t, J 11.6), 2.20-2.35 (2H, m), 3.08 (2

- 27 -

H, d, J 6.5), 4.06 (2H, s), 7.48 (2H, t, J 8.9), 7.71 (2H, t, J 8.8), 8.11 (2H, dd, J 5.2 and 8.7), 8.20 (2H, dd, J 5.6 and 8.9). m/z (ES^+) 398 [MH] $^+$.

EXAMPLE 44

5

(*RS*)-4-Fluoro-1-[2-fluoro-2-(4-fluorophenyl)ethyl]-4-(4-fluorophenylsulfonyl)piperidine

Sodium borohydride (20 mg, 0.5 mmol) was added to a suspension of 2-[4-fluoro-4-(4-fluorophenylsulfonyl)piperidin-1-yl]-1-(4-fluorophenyl)ethanone (40 mg, 0.1 mmol) in EtOH (5 mL) and the mixture stirred at ambient temperature for 1 h. The resulting solution was concentrated *in vacuo* and the residue partitioned between water (20 mL) and EtOAc (20 mL). The organic portion was dried over Na_2SO_4 , filtered and concentrated to afford (*RS*)-2-[4-fluoro-4-(4-fluorophenylsulfonyl)piperidin-1-yl]-1-(4-fluorophenyl)ethanol as a white solid: m/z (ES^+) 418 [MH] $^+$.

(*RS*)-2-[4-Fluoro-4-(4-fluorophenylsulfonyl)piperidin-1-yl]-1-(4-fluorophenyl)ethanol was converted to the title compound as described in Example 42: δ_H (500 MHz, DMSO) 1.78-1.82 (2H, m), 2.05-2.20 (2H, m), 2.25-2.32 (2H, m), 2.63-2.72 (1H, m), 2.88-3.04 (3H, m), 5.67-5.79 (1H, m), 7.21-7.25 (2H, m), 7.43-7.48 (2H, m), 7.56-7.60 (2H, m), 7.96-7.99 (2H, m). m/z (ES^+) 402 [MH] $^+$.

The following compounds (Examples 45-48) were prepared using analogous methods to Examples 42-44:

4-({4-Fluoro-1-[2-(4-fluorophenyl)-2-oxoethyl]piperidin-4-yl}sulfonyl)benzonitrile
 m/z (ES^+) 405 [MH] $^+$.

1-(4-Fluorophenyl)-2-[4-fluoro-4-(phenylsulfonyl)piperidin-1-yl]ethanone
 m/z (ES^+) 380 [MH] $^+$.

30

- 28 -

(RS)-4-({1-[2-(2,4-Difluorophenyl)-2-fluoroethyl]-4-fluoropiperidin-4-yl}sulfonyl)benzamide

m/z (ES⁺) 445 [MH]⁺.

5 (RS)-4-({4-Fluoro-1-[2-fluoro-2-(4-fluorophenyl)ethyl]piperidin-4-yl}sulfonyl)benzamide

m/z (ES⁺) 427 [MH]⁺.

EXAMPLE 49

10


(RS)-1-[2-(2,4-Difluorophenyl)-1-methylethyl]-4-fluoro-4-(4-fluorophenylsulfonyl)piperidine

Titanium tetrakisopropoxide (0.29 mL, 1.4 mmol) was added to a solution of 4-fluoro-4-(4-fluorophenylsulfonyl)piperidine (179 mg, 0.68 mmol) and 2,4-difluorophenylacetone (116 mg, 0.68 mmol) in EtOH (3.4 mL) and the mixture stirred at ambient temperature for 16 h. Sodium borohydride was added (41 mg, 1.0 mmol) and stirring continued for 2 h. Water (20 mL) and EtOAc (20 mL) were added and the bi-phasic mixture was filtered through Hyflo[®]. The filtrate was partitioned and the organic portion dried over Na₂SO₄, filtered and concentrated *in vacuo*. Purification by column chromatography (silica, 50% EtOAc/isohexane) afforded semi-pure material which was further purified by treatment with a 1 N solution of HCl in Et₂O, followed by washing of the solid residue with further Et₂O, yielding the title compound as the hydrogen chloride salt: δ_H (500 MHz, DMSO) 1.09-1.19 (3H, m), 2.14-2.21 (2H, m), 2.53-2.60 (1H, m), 2.68-2.85 (3H, m), 3.13-3.56 (5H, m), 7.08-7.14 (1H, m), 7.22-7.28 (1H, m), 7.41-7.48 (1H, m), 7.60-7.67 (2H, m), 8.00-8.07 (2H, m), 11.10-11.20 (br s). *m/z* (ES⁺) 416 [MH]⁺.

25

CLAIMS:

1. A compound of formula I:



or a pharmaceutically acceptable salt thereof wherein:

Ar is phenyl, benzisothiazol-3-yl or benzthiophen-3-yl, each of which bears substituent groups R^1 , R^2 and R^3 ;

- 10 R^1 is hydrogen, fluorine, chlorine, bromine, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{2-6} alkenyloxy, C_{2-6} alkynyloxy, or C_{1-6} alkyl substituted by up to 5-fluorine atoms;

R^2 is hydrogen, fluorine, chlorine, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkyl substituted by up to 5 fluorine atoms or C_{1-4} alkoxy substituted by up to 5 fluorine atoms;

- 15 R^3 is hydrogen, fluorine, chlorine, methyl, methoxy, trifluoromethyl, difluoromethyl, trifluoromethoxy or difluoromethoxy;

- Q^1 is hydrogen; fluorine; chlorine; bromine; C_{1-6} alkyl; C_{3-6} cycloalkyl; C_{2-6} alkenyl; C_{2-6} alkynyl; C_{1-6} alkoxy; C_{2-6} alkenyloxy; C_{2-6} alkynyloxy; C_{1-6} alkyl substituted by up to 5-fluorine atoms; nitrile; COQ^4 or CO_2Q^4 where Q^4 is hydrogen or C_{1-6} alkyl; NQ^5Q^6 , $CONQ^5Q^6$ or $SO_2NQ^5Q^6$ where Q^5 is hydrogen or C_{1-6} alkyl and Q^6 is hydrogen or C_{1-6} alkyl or Q^5 and Q^6 are joined to form either a 4-7 membered heterocyclic ring which may also contain one oxygen or one further nitrogen ring atom, which heterocyclic ring may optionally be substituted by up to 3 fluorine atoms or by CF_3 , methyl, ethyl or hydroxyl; hydroxyl; nitro; SOQ^7 or SO_2Q^7 where Q^7 is C_{1-4} alkyl; NQ^8COQ^9 , $NQ^8CO_2Q^9$ or $NQ^8SO_2Q^9$ where Q^8 is hydrogen or C_{1-4} alkyl and Q^9 is hydrogen or C_{1-4} alkyl or is joined to Q^8 to form a 5-7 membered ring; a heteroaromatic ring of 5 ring atoms 1, 2, 3 or 4 of which may be nitrogen atoms or 1 or 2 of which are nitrogen atoms and 1 of which is an oxygen or sulfur atom or 1 of

- 30 -

which is an oxygen or sulfur atom, which heteroaromatic ring optionally being substituted by methyl, ethyl or hydroxyl; or a heteroaromatic ring of 6 ring atoms containing 1 or 2 nitrogen ring atoms or a phenyl group either of which is optionally substituted by 1 or 2 fluorine or chlorine atoms or C₁₋₄alkyl, C₁₋₄alkoxy or trifluoromethyl groups;

Q² is hydrogen, fluorine, chlorine, nitrile, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkyl substituted by up to 5 fluorine atoms, or C₁₋₄ alkoxy substituted by up to 5 fluorine atoms;

Q³ is hydrogen, fluorine, chlorine, methyl, methoxy, trifluoromethyl, difluoromethyl, trifluoromethoxy or difluoromethoxy;

or Q² and Q³ are joined to form the residue of a 5, 6 or 7 membered carbocyclic ring;

R⁴ is H or C₁₋₄ alkyl,

m is 0 or 1;


n is 0, 1 or 2; and

W is CH₂, CHF, CH(OH) or CO.

2. A compound according to claim 1 wherein Ar represents benzisothiazol-3-yl or benzthiophen-3-yl, each bearing substituent groups R¹, R² and R³, and m and n are both 0.

3. A compound according to claim 1 wherein Ar represents phenyl bearing substituent groups R¹, R² and R³, m is 1 and n is 0.

4. A compound according to claim 1 of formula IIA:



(IIA)

- 31 -

or a pharmaceutically acceptable salt thereof;

wherein R^{13} represents H and R^{14} represents H, F or OH, or R^{13} and R^{14} together represent keto;

and Q^1 , Q^2 , R^1 , R^2 and R^4 are as defined in claim 1.

5

5. A compound according to any previous claim wherein Q^1 is selected from H, F, Cl, Br, CN, carboxamide, 5-membered heteroaryl and NQ^5Q^6 where Q^5 and Q^6 complete a heterocyclic ring;

Q^2 is H, F or Cl;

10

Q^3 is H or F;

R^1 is H, F, methyl or CF_3 ;

R^2 is H, F, methyl or CF_3 ; and

R^3 is H.

15

6. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

7. A compound according to claim 1 for use in a method of treatment of the human body.

20

8. The use of a compound according to claim 1 for the manufacture of a medicament for treating or preventing a condition mediated by 5-HT_{2A} receptor activity.

25

9. A method of treatment of a subject suffering from or prone to a condition mediated by 5-HT_{2A} receptor activity which comprises administering to that subject an effective amount of a compound according to claim 1.

30

THIS PAGE BLANK (USPTO)

INTERNATIONAL SEARCH REPORT

ational Application No
/GB2004/001998

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/54 C07D417/06 C07D401/12 C07D413/12 A61K31/445
A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/51469 A (ACKERMANN KARL AUGUST ; AMSTERDAM CHRISTOPH VAN (DE); BOETTCHER HENNIN) 19 July 2001 (2001-07-19) the whole document	1-9
Y	WO 00/43362 A (CHENG SUSAN KOON FUNG ; FLETCHER STEPHEN ROBERT (GB); MERCK SHARP & DO) 27 July 2000 (2000-07-27) cited in the application the whole document	1-9
Y	S. R. FLETCHER ET AL.: "4-(Phenylsulfonyl)piperidines: Novel, Selective, and Bioavailable 5-HT _{2A} Receptor antagonists" J. MED. CHEM., vol. 45, no. 2, 2002, XP002290071 cited in the application examples	1-9

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

27 July 2004

Date of mailing of the international search report

11/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lauro, P

INTERNATIONAL SEARCH REPORT

International Application No

/GB2004/001998

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0151469	A	19-07-2001	DE 10000739 A1	12-07-2001
			AU 3368501 A	24-07-2001
			BR 0107578 A	01-10-2002
			CA 2396007 A1	19-07-2001
			CN 1394203 T	29-01-2003
			CZ 20022309 A3	16-10-2002
			WO 0151469 A1	19-07-2001
			EP 1246803 A1	09-10-2002
			HU 0300052 A2	28-05-2003
			JP 2004500373 T	08-01-2004
			NO 20023293 A	08-07-2002
			PL 355654 A1	04-05-2004
			SK 9712002 A3	03-12-2002
			US 2003130287 A1	10-07-2003
			ZA 200206361 A	10-11-2003
WO 0043362	A	27-07-2000	AT 267171 T	15-06-2004
			AU 773296 B2	20-05-2004
			AU 3064700 A	07-08-2000
			CA 2359983 A1	27-07-2000
			DE 60010855 D1	24-06-2004
			EP 1147084 A1	24-10-2001
			WO 0043362 A1	27-07-2000
			JP 2002535308 T	22-10-2002
			US 2003203889 A1	30-10-2003
			US 6559166 B1	06-05-2003